Previous close | 1.8500 |
Open | 1.7000 |
Bid | 1.6000 x 0 |
Ask | 1.9000 x 0 |
Day's range | 1.7000 - 1.7000 |
52-week range | 1.3100 - 2.5000 |
Volume | |
Avg. volume | 140,061 |
Market cap | 16.324M |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings date | 21 Mar 2023 - 27 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.
Medtronic (NYSE: MDT) may be a leader in the medical device space, but its sluggish 1.3% revenue growth over the past three years has not kept pace with the 5% growth of the medical device market. Medtronic's Surgical Innovations segment achieved robust growth over the past year. Its 9% revenue growth overshadowed the 2%-3% revenue growth from the Cardiovascular and Neuroscience segments.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...